Machado Patrick 4

What Happened

• Patrick Machado, a director of Xenon Pharmaceuticals (XENE), had 2,645 RSUs vest on June 1, 2026 and those shares were reported as both acquired (conversion) and disposed at $0.00 (derivative entry). On June 3, 2026 he was granted two RSU awards totaling 12,100 RSUs (10,507 and 1,593) reported at $0.00 (awards/derivative). No cash proceeds or market sales were reported.

Key Details

• Transaction types: M = exercise/conversion of derivative (vested RSUs converted to common shares); A = grant/award of RSUs.
• Dates and reported prices:
  • 2026-06-01: 2,645 shares acquired via conversion (M) — price N/A; same day 2,645 shares reported disposed at $0.00 (M).
  • 2026-06-03: 10,507 RSUs acquired (A) at $0.00; 1,593 RSUs acquired (A) at $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 2,645 shares reflect RSUs granted June 5, 2025 that vested 100% on June 1, 2026.
  • F2/F3: The new RSU awards vest 100% on the earlier of (i) June 1, 2027 or (ii) the day before the issuer's 2027 annual meeting; each RSU represents the contingent right to one common share.
• Filing timeliness: Report filed June 3, 2026 for transactions on June 1 and June 3; no late filing flag shown in the excerpt.

Context

• RSU vesting/conversion (M) means the derivative converted into actual shares; a simultaneous disposal at $0.00 commonly reflects shares withheld to satisfy tax withholding or net settlement rather than an open-market sale, though the filing does not explicitly state the reason.
• The June 3 entries are grants of RSUs (contingent rights to shares) that vest next year — these are compensation awards, not immediate purchases or sales.
• Awards and tax-withholding-related dispositions are routine insider compensation activity and do not necessarily indicate a buy/sell signal about management’s view of the stock.